EGFR, epidermal growth factor receptor, 1956

N. diseases: 1394; N. variants: 183
Disease: Papulopustular Rash ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2609319
Disease: Papulopustular Rash
Papulopustular Rash 		0.030 GeneticVariation phenotype BEFREE <b>Background:</b> Papulopustular rash is the most common cutaneous adverse effect during targeted tumour therapy particularly with epidermal growth factor receptor inhibitors (EGFRIs). 31010330 2019
CUI: C2609319
Disease: Papulopustular Rash
Papulopustular Rash 		0.030 GeneticVariation phenotype BEFREE The majority of patients with mCRC who are treated with anti-EGFR therapy develop skin toxicities, including papulopustular rash (the most common), xerosis, painful cracks and fissures on the palms and soles of the feet, paronychia, pruritus, and abnormal hair and eyelash growth; they are also more prone to skin infections. 31264159 2019
CUI: C2609319
Disease: Papulopustular Rash
Papulopustular Rash 		0.030 Biomarker phenotype BEFREE Skin conditions are the most common toxicities associated with EGFR inhibitors, particularly papulopustular rash. 28477738 2017